• LAST PRICE
    2.3900
  • TODAY'S CHANGE (%)
    Trending Up0.1500 (6.6964%)
  • Bid / Lots
    2.2400/ 3
  • Ask / Lots
    2.4000/ 2
  • Open / Previous Close
    2.3600 / 2.2400
  • Day Range
    Low 2.3175
    High 2.3920
  • 52 Week Range
    Low 2.1000
    High 8.8000
  • Volume
    969
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 2.24
TimeVolumeAKTX
09:51 ET1002.36
11:20 ET1002.3175
01:18 ET2062.392
01:33 ET1002.34
01:36 ET1002.39
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAKTX
Akari Therapeutics PLC
14.8M
-0.4x
---
United StatesAGE
AgeX Therapeutics Inc
14.8M
-1.1x
---
United StatesNNVC
NanoViricides Inc
14.4M
-1.6x
---
United StatesMIRA
Mira Pharmaceuticals Inc
15.4M
0.0x
---
United StatesIKT
Inhibikase Therapeutics Inc
14.6M
-0.6x
---
United StatesOTLC
Oncotelic Therapeutics Inc
15.7M
-1.2x
---
As of 2024-02-20

Company Information

Akari Therapeutics, Plc is a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. The Company's lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The Company has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the United States Food and Drug Administration (FDA) for nomacopan for the treatment of pediatric HSCT-TMA. Additionally, the Company has a pre-clinical program developing long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD).

Contact Information

Headquarters
22 BOSTON WHARF ROAD, FL 7BOSTON, MA, United States 02210
Phone
646-350-0702
Fax
646-843-9352

Executives

Non-Executive Chairman of the Board
Raymond Prudo-chlebosz
President, Chief Executive Officer, Director
Rachelle Jacques
Interim Chief Financial Officer
Wendy Dicicco
Chief Operating Officer
Melissa Bradford-klug
Senior Vice President - Regulatory Affairs
Bethanne Lang

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$14.8M
Revenue (TTM)
$0.00
Shares Outstanding
330.0K
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.04
EPS
$-5.68
Book Value
$0.48
P/E Ratio
-0.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.